TNF-alpha inhibitors and leukaemia: international pharmacovigilance reports

Drug Saf. 2008;31(5):445-7. doi: 10.2165/00002018-200831050-00013.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adalimumab
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / drug therapy
  • Child
  • Child, Preschool
  • Crohn Disease / complications
  • Crohn Disease / drug therapy
  • Databases, Factual
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / adverse effects
  • Immunoglobulin G / therapeutic use
  • Infant
  • Infliximab
  • Leukemia / chemically induced*
  • Leukemia / epidemiology*
  • Male
  • Middle Aged
  • Product Surveillance, Postmarketing
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab
  • Etanercept